Susan M. O'Brien, MD
Chemotherapy is becoming less of a priority in the treatment paradigm of chronic lymphocytic leukemia (CLL) with the addition of the FDA-approved novel agents ibrutinib (Imbruvica), idelalisib (Zydelig), and venetoclax (Venclexta), explained Susan M. O’Brien, MD.
For example, data have strongly indicated that patients with CLL who have a 17p deletion will not respond to chemotherapy. Chimeric antigen receptor (CAR) T-cell therapy could be an alternative for these patients in an early setting, O’Brien said.
... to read the full story